Compass Therapeutics, Inc. CMPX 深 沪
已收盘 09-19 16:00:00 美东时间
3.39
-0.290
-7.88%
华盛通- 最 高3.81
- 今 开3.80
- 成交量 670.92万股
- 最 低 3.38
- 昨 收 3.68
- 总市值 4.68亿
- 52周最高 4.08
- 市盈率 静 --
- 换手率 4.86%
- 52周最低 1.27
- 委 比 -97.33%
- 总股本 1.38亿
- 历史最高 5.65
- 量 比 8.05
- 振 幅 11.68%
- 历史最低 0.765
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Compass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for treating multiple human diseases, will participate in four investor events in September 2025. These include Citi’s Biopharma Back to School Conference in Boston on September 2, the Cantor Global Healthcare Conference in New York on September 3, H.C. Wainwright’s Global Investment Conference in New York on September 8, and Morgan Sta...
08-26 12:00
Compass Therapeutics dips 5%, prices $120M stock
Compass Therapeutics (NASDAQ:CMPX) priced an underwritten public offering of 33.29M shares at $3.00 per share and pre-funded warrants to purchase up to 6.67M shares. The gross proceeds are expected ...
08-13 13:48
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Compass Therapeutics宣布公开发行3329万股普通股，每股定价3美元，同时发行671万股预存股票期权，每股2.9999美元，预计筹资约1.2亿美元，用于商业准备、研究与临床开发及一般公司用途。
08-13 02:28
Compass Therapeutics Announces Proposed Public Offering
Compass Therapeutics announced the launch of an underwritten public offering of its common stock and pre-funded warrants to purchase shares of common stock. The company plans to use proceeds for commercial readiness, research, clinical development, and general corporate purposes. Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint active bookrunning managers. The offering is subject to market conditions and SEC registration. C...
08-12 20:01
Compass Therapeutics rises after pipeline updates
Shares of Compass Therapeutics (NASDAQ:CMPX) added ~21% on Monday after the cancer drug developer, with its Q2 2025 results, announced a lower-than-expected number of mortalities in a Phase 2/3 trial ...
08-12 01:55
Compass Therapeutics Q2 EPS $(0.14) Misses $(0.12) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 13.82 percent. This is a 40 percent decrease over losses of $(0.10) per share
08-11 19:03
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported Q2 2025 results, highlighting progress in their oncology pipeline. Tovecimig showed fewer deaths than expected in its Phase 2/3 study, potentially impacting overall survival, with secondary endpoint analyses delayed to Q1 2026. CTX-8371 demonstrated promising responses in lung and breast cancer patients, with cohort expansions planned. CTX-10726 showed superior activity in preclinical studies, with IND filing expecte...
08-11 11:00
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, will release its Q2 2025 financial results and host a webcast/conference call on Monday, August 11, 2025, at 8:00 AM ET. The event will provide updates on the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726. The call can be accessed via dial-in numbers 1-877-407-9716 (US) or 1-201-493-6779 (Intl.), using conference ID 13754...
08-08 20:01
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
